Provided by Tiger Trade Technology Pte. Ltd.

Aclaris Therapeutics

6.02
-0.0300-0.50%
Post-market: 6.020.00000.00%19:30 EDT
Volume:1.49M
Turnover:8.96M
Market Cap:886.14M
PE:-10.27
High:6.24
Open:6.09
Low:5.95
Close:6.05
52wk High:6.60
52wk Low:1.74
Shares:147.20M
Float Shares:110.00M
Volume Ratio:0.80
T/O Rate:1.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5861
EPS(LYR):-0.5300
ROE:-59.10%
ROA:-28.98%
PB:7.11
PE(LYR):-11.36

Loading ...

Aclaris Therapeutics Initiated at Buy by Canaccord Genuity

Dow Jones
·
13 hours ago

Aclaris Therapeutics, Inc. : Canaccord Genuity Initiates Coverage with Buy Rating; Target Price $10

THOMSON REUTERS
·
Yesterday

Canaccord Genuity Initiates Aclaris Therapeutics at Buy With $10 Price Target

MT Newswires Live
·
Yesterday

Aclaris Therapeutics initiated with a Buy at Canaccord

TIPRANKS
·
Yesterday

U.S. Research Roundup-Autodesk, Hubspot, Oracle

Reuters
·
Yesterday

Piper Sandler Sticks to Their Buy Rating for Aclaris Therapeutics (ACRS)

TIPRANKS
·
Aug 31

Aclaris Therapeutics Enters Amended At-the-Market Equity Sales Agreement with Leerink, Cantor

Reuters
·
Aug 07

Aclaris Says FDA Grants Fast Track Status for Modzatinib in Moderate to Severe Lichen Planus

Reuters
·
Aug 07

Aclaris Therapeutics Gets Fast-Track Designation for Inflammation Treatment Modzatinib

Dow Jones
·
Aug 07

Aclaris Therapeutics receives FDA Fast Track Designation for Modzatinib

TIPRANKS
·
Aug 07

Aclaris Therapeutics, Inc. Files for Mixed Shelf; Size not Disclosed - SEC Filing

THOMSON REUTERS
·
Aug 07

Aclaris Therapeutics, Inc.: Expects to Initiate a Phased Multi-Part Phase 2B Trial of Modzatinib in Lp in Q4 of 2026

THOMSON REUTERS
·
Aug 07

Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (Lp)

THOMSON REUTERS
·
Aug 07

Craig-Hallum Sticks to Their Buy Rating for Aclaris Therapeutics (ACRS)

TIPRANKS
·
Aug 06

Aclaris Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Aclaris Q2 FY26 Net Loss Widens to $21.5 Million; Revenue Slips to $1.6 Million

Reuters
·
Aug 06

Aclaris Therapeutics Q2 Revenue Beats Analyst Estimates

Reuters
·
Aug 06

Earnings Flash (ACRS) Aclaris Therapeutics Posts Q2 Net Loss $0.15 a Share, vs. FactSet Est of $0.16 Loss

MT Newswires Live
·
Aug 06

Aclaris Therapeutics Q2 EPS $(0.15) Beats $(0.16) Estimate, Sales $1.629M Beat $1.383M Estimate

Benzinga Earnings
·
Aug 06

Aclaris Therapeutics, - Expects Cash to Fund Operations Through End of 2028

THOMSON REUTERS
·
Aug 06